US NEWPORT CONSTRAINT DATE 2020

EVEROLIMUS (CAS 159351-69-6) is a derivative of natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties.

THERAPEUTIC INDICATION: ONCOLOGY

EVEROLIMUS is an oral prescription-strength medicine approved to treat certain types of cancer including advanced hormone receptor-positive, HER2-negative breast cancer, and advanced renal cell carcinoma. It is also indicated for the prophylaxis of organ rejection in kidney or liver transplantation.

MARKET INFORMATION

Originator: NOVARTIS

Originator products:

AFINITOR^® as antineoplastic agent
ZORTRESS^® as immunosuppressant

YOUR ADVANTAGES

Our EVEROLIMUS can be tailored to your needs e.g. we can offer a customized BHT content of 2%, 1.2%, and 0%
Few API sources active in the market

^{This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.}